Another arm of Lung-MAP evaluates selpercatinib as a single-agent in the same disease setting.66 Selpercatinib is also being studied as part of the phase 2 platform study (ORCHARD; NCT03944772) in patients with advanced NSCLC who progressed after treatment with first-line osimertinib.67 This is also the case in the phase 2 Finnish trial (FINPROVE) which includes patients with advanced solid tumors that harbor a RET alteration.68 This evidence concerns the gene RET and non-small cell lung carcinoma.